Parkinson’s research boosted with BioFocus/Michael J Fox Foundation collaboration

Thursday, 14 July, 2011

BioFocus has signed a collaboration agreement with The Michael J Fox Foundation for Parkinson’s Research, a not-for-profit organisation focused on developing therapies for Parkinson’s disease. Under the agreement, BioFocus will perform fragment-based screening, assay development and hit-finding programs to identify compounds that have the basis for a novel Parkinson’s disease diagnostic test.

As the world’s largest private funder of Parkinson’s research, The Michael J Fox Foundation is dedicated to accelerating a cure for Parkinson’s disease and improved therapies for those living with the condition today. The foundation pursues its goals through a targeted research program coupled with active global engagement of scientists, Parkinson’s patients, business leaders, clinical trial participants, donors and volunteers.

In addition to funding over $240 million in research to date, the foundation has fundamentally altered the trajectory of progress towards a cure. Operating at the hub of worldwide Parkinson’s research, the foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases Parkinson’s awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world.

Related News

Vaxxas appoints former Merck Global Vaccines President David Peacock as CEO

To lead the commercialisation of Vaxxas's proprietary high‑density microarray patch (HD‑MAP)...

Optics11 Life appoints Jacquelien ten Dam as CEO

Optics11 Life plans to accelerate its commercial growth in key markets while building strategic...

Epilepsy pioneer elected President of Aust Academy of Science

Laureate Professor Sam Berkovic — one of the world's most respected neurologists...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd